

Available as an optional add-on for publicly funded patients only. Additional fees apply.

Ordering Healthcare Provider		Copy to Healthcare Provider	
Billing #:		Billing #:	
Name:		Name:	
Patient information			
Last name:			
First name:			
Date of birth: MM / DD / YYYY			
I confirm that I have completed and signed this requisition, and am providing it to my patient along with the publicly funded Panorama™ requisition.			
I acknowledge that I have informed my patient that microdeletion panels are not publicly funded and is available as an optional service for an additional fee. Payment may be made by the patient when the blood sample is collected at one of our Patient Service Centres or by contacting our Genetics Customer Support Team at 1-844-363-4357.			
Physician signature: _____			

Add-on requested (select one)	Cost	LL code
<input type="checkbox"/> 22q11.2 deletion syndrome (only available for singleton and monozygotic twin pregnancies)	\$100	3037
<input type="checkbox"/> Microdeletion Extended Panel (only available for singleton pregnancies)	\$245	3071

For convenience, Visa, Mastercard and Debit Cards are accepted at our patient service centres.

For microdeletion testing: Testing may show that you are at high risk for carrying a 22q11.2 deletion. If so, the Panorama™ report will state that you have a 1 in 2 or 50% chance for an affected pregnancy (as fetal status cannot be determined in this case). Pregnant individuals who do not wish to risk finding out whether they carry this microdeletion should consider opting out of the microdeletion portion of the screening test. If the pregnant individual is found to be a carrier of one of the other microdeletions on this panel, this screen will not be able to return results on the fetus. If you know you carry one of the microdeletions on this screen, it is recommended that you use another form of testing if you wish to determine the presence or absence of that microdeletion in your fetus. If the percentage of fetal (placental) DNA in the sample is below 7%, screening for Angelman syndrome will not be performed and the results will be reported as “risk unchanged”. A redraw will not be recommended and, if so chosen by the ordering healthcare provider, the cost will be borne by the patient.